ArticleNature nanotechnology2024
Multimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections.
Article in Nature nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 81 citations in OpenAlex.
- Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.Bioactive materials · 2026Review
- Dual-Targeted Biomimetic MoSeAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Versatile Targeted Celastrol Nanoassemblies for Enhanced Immunomodulatory Effects Against MRSA Infection.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Artificial exosomes synergistically reshape sepsis immune homeostasis by modulating neutrophil fate and blocking PD-1/PD-L1.Cell reports. Medicine · 2026Article
- Cell-based drug delivery for combating bacteria: focus on refractory infections.Journal of nanobiotechnology · 2026Review
- A robust adhesive microneedle for oral infections therapy via synergistic antibacterial and neutrophil-macrophage axis immunomodulation.Science advances · 2026Article
- Reprogramming Lesional Macrophage Homeostasis via Interferon Regulatory Factor 5 Targeted siRNA Nanoimmunotherapy for Atherosclerosis.ACS nano · 2026Article
- Ultrasound-activated MoS₂@Fe₃O₄ nanoplatform orchestrates biofilm disruption and immune reprogramming in implant-associated infections.Journal of nanobiotechnology · 2026Article
- Synergistic chemodynamic-photothermal therapy of super-resistant Enterobacter asburiae-infected sepsis using multifunctional mesoporous nanocomposite.Journal of nanobiotechnology · 2026Article
- Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy.Cell reports. Medicine · 2026Article
- Nanomedicine applications for the treatment of Staphylococcus aureus infections.FEMS microbiology reviews · 2026Review
- Overcoming Methicillin-ResistantResearch (Washington, D.C.) · 2026Article
- Precision Nanodelivery Enables Spatiotemporal Control of NAD⁺ Metabolism in Ageing and Disease.International journal of nanomedicine · 2026Review
- Nanomedicine against antimicrobial resistance: mechanistic insights and next-generation therapeutic potential.Frontiers in chemistry · 2026Review
- HJournal of nanobiotechnology · 2025Article
- Engineered cellular drug delivery: Strategies and applications.Materials today. Bio · 2025Review
- Hemoglobin nanocatalyst with tunable autoxidation activity for tumor apoptosis-ferroptosis combination therapy.Acta pharmaceutica Sinica. B · 2025Article
- Harnessing biomaterials for tuning inflammation: A neutrophil-centric perspective.Materials today. Bio · 2025Review
- Engineered Phage-Guided Nanotherapeutic Systems for Precision Antibacterial Therapy: Hacking Bacterial Resistance Mechanisms.Pharmaceutics · 2025Review
- Novel ST-Specific Molecular Target-Based Method for Simultaneous and Quantitative Detection ofMolecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The increasing prevalence of antimicrobial resistance in Staphylococcus aureus necessitates alternative therapeutic approaches. Neutrophils play a crucial role in the fight against S. aureus but suffer from deficiencies in function leading to increased infection. Here we report a nanoparticle-mediated immunotherapy aimed at potentiating neutrophils to eliminate S. aureus. The nanoparticles consist of naftifine, haemoglobin (Hb) and a red blood cell membrane coating. Naftifine disrupts staphyloxanthin biosynthesis, Hb reduces bacterial hydrogen sulfide levels and the red blood cell membrane modifies bacterial lipid composition. Collectively, the nanoparticles can sensitize S. aureus to host oxidant killing. Furthermore, in the infectious microenvironment, Hb triggers lipid peroxidation in S. aureus, promoting neutrophil chemotaxis. Oxygen supplied by Hb can also significantly enhance the bactericidal capability of the recruited neutrophils by restoring neutrophil respiratory burst via hypoxia relief. This multimodal nanoimmunotherapy demonstrates excellent therapeutic efficacy in treating antimicrobial-resistant S. aureus persisters, biofilms and S. aureus-induced infection in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.